-
Malaysia declares haze emergency in Sarawak state on Borneo
-
Stocks mixed before US jobs data, oil dips
-
East German refinery adjusts to life without Russian oil
-
Optimised urinals and buried underwear at 2026 Ig Nobels
-
Song Yadong looks to become China's first UFC champion after home victory
-
German factory orders rise again in latest recovery sign
-
India's Mandhana becomes top run-scorer in women's cricket
-
Nepal's 'Himalayan tsunami': what we know
-
IUX Announces Two New Podcast Series: IUX Market Trendline and The Market Journey
-
SPAYZ.io brings Africa’s payment growth story to Forex Expo Dubai 2026
-
Brussels Diamond League finals Day 2 - four events to watch
-
Zelensky slams his security services for 'unacceptable' shootout
-
Looming far-right win in Germany sparks security worries
-
Farage's Reform UK meets as new donation scandal hits
-
Tanker captain arrested over cargo ship sinking off Istanbul
-
Volunteers fight uphill battle against Indonesian fires
-
India hopes 'unique idea' will save athletes from cabin fever
-
PU Prime Launches Australian Operations under ASIC Licence
-
UK asserts 'unshakeable' Falklands commitment after Milei presses claim
-
Night-owl Zverev goes distance to advance as upsets rock US Open
-
How a Dostoevsky novella took TikTok by storm
-
Marathon man Zverev goes distance again to reach US Open third round
-
Zverev goes the distance again to reach US Open third round
-
US study tests psilocybin to fight cancer side effects
-
German AfD's love for Simson mopeds dismays Jewish family behind brand
-
Italy's Meloni throws party to celebrate record in power
-
Two trapped tunnel workers rescued in Nepal 'miracle'
-
After heatwaves, will EU pivot back to the climate fight?
-
Ex-Pakistan coach Gillespie tells Javed 'look in the mirror' over sackings
-
South Korean football referee faces hearing over 'period' insult
-
Monfils falls to Tien in US Open in Grand Slam farewell
-
Toulouse eye Top 14 history after 'difficult' summer
-
Arsenal brace for Chelsea test as Spurs seek spark
-
Springboks and All Blacks seek series lead after war of words
-
Efficient Rybakina reaches US Open third round
-
Bundesliga brings the band back together in Premier League's shadow
-
Taiwan boxer Lin considered 'graceful exit' after Paris Games gold
-
Asian stocks rally as traders pare rate bets ahead of jobs data
-
'I miss my home': Cambodians displaced by conflict start over
-
War-bruised Myanmar finds relief in bareknuckle bloodsport
-
Ailing Auger-Aliassime falls at US Open as Swiatek, Osaka and Gauff advance
-
Gauff downs Badosa to reach US Open third round
-
Tesla launches self-driving 'Cybercab' in Texas
-
New Zealand approves use of party drug MDMA to treat trauma
-
'Wallace & Gromit' creators turn 50 with spook-tacular Shaun yarn
-
Westerners test their mettle at World Nomad Games in Kyrgyzstan
-
New York's Muslims reclaim their city after 9/11 backlash
-
Gauff cruises into US Open third round
-
Premier League transfer windfall a lifeline for ailing French clubs
-
Kyrgios gets month ban for cocaine, enters treatment programme
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
O.Norris--AMWN